Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Journal for ImmunoTherapy of Cancer

Hideho Okada³  Atsushi Natsume²  Carl H June⁴  Kuniaki Tanahashi²  Akemi Kosaka¹  Takayuki Ohkuri¹  Masasuke Ohno¹ 

[1] Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA;Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan;Department of Immunology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA;Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

关键词: Adoptive immunotherapy;    Glioblastoma;    Chimeric antigen receptor;    miR-17-92;    microRNA;   

Others  :  814871
DOI  :  10.1186/2051-1426-1-21

 received in 2013-06-18, accepted in 2013-12-05,  发布年份 2013

【 摘 要 】

Background

Expression of miR-17-92 enhances T-cell survival and interferon (IFN)-γ production. We previously reported that miR-17-92 is down-regulated in T-cells derived from glioblastoma (GBM) patients. We hypothesized that transgene-derived co-expression of miR17-92 and chimeric antigen receptor (CAR) in T-cells would improve the efficacy of adoptive transfer therapy against GBM.

Methods

We constructed novel lentiviral vectors for miR-17-92 (FG12-EF1a-miR-17/92) and a CAR consisting of an epidermal growth factor receptor variant III (EGFRvIII)-specific, single-chain variable fragment (scFv) coupled to the T-cell receptor CD3ζ chain signaling module and co-stimulatory motifs of CD137 (4-1BB) and CD28 in tandem (pELNS-3C10-CAR). Human T-cells were transduced with these lentiviral vectors, and their anti-tumor effects were evaluated both in vitro and in vivo.

Results

CAR-transduced T-cells (CAR-T-cells) exhibited potent, antigen-specific, cytotoxic activity against U87 GBM cells that stably express EGFRvIII (U87-EGFRvIII) and, when co-transduced with miR-17-92, exhibited improved survival in the presence of temozolomide (TMZ) compared with CAR-T-cells without miR-17-92 co-transduction. In mice bearing intracranial U87-EGFRvIII xenografts, CAR-T-cells with or without transgene-derived miR-17-92 expression demonstrated similar levels of therapeutic effect without demonstrating any uncontrolled growth of CAR-T-cells. However, when these mice were re-challenged with U87-EGFRvIII cells in their brains, mice receiving co-transduced CAR-T-cells exhibited improved protection compared with mice treated with CAR-T-cells without miR-17-92 co-transduction.

Conclusion

These results warrant the development of novel CAR-T-cell strategies that incorporate miR-17-92 to improve therapeutic potency, especially in patients with GBM.

【 授权许可】

   
2013 Ohno et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Okada H, et al.: Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009, 29:1-42.
• [2]Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA: The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol 2012, 13:437-450.
• [3]Ruzevick J, Jackson C, Phallen J, Lim M: Clinical trials with immunotherapy for high-grade glioma. Neurosurg Clin N Am 2012, 23:459-470.
• [4]Okada H, et al.: Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With {alpha}-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011, 29:330-336.
• [5]Kalos M, et al.: T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci Transl Med 2011, 3:95ra73.
• [6]Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 2011, 365:725-733.
• [7]Brentjens RJ, et al.: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
• [8]Kochenderfer JN, et al.: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
• [9]Facoetti A, et al.: Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005, 11:8304-8311.
• [10]Yeung JT, et al.: LOH in the HLA Class I region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clin Cancer Res 2013. Epub ahead of print
• [11]Pule MA, et al.: A Chimeric T Cell Antigen Receptor that Augments Cytokine Release and Supports Clonal Expansion of Primary Human T Cells. Mol Ther 2005, 12:933-941.
• [12]Carpenito C, et al.: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 2009, 106:3360-3365.
• [13]Imai C, et al.: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
• [14]Moeller M, et al.: A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004, 11:371-379.
• [15]Morgan RA, et al.: Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther 2010, 18:843-851.
• [16]Hatanpaa KJ, Burma S, Zhao D, Habib AA: Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684.
• [17]Mukasa A, et al.: Mutant EGFR is required for maintainenece of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010, 107:2616-2621.
• [18]Heimberger AB, Suki D, Yang D, Shi W, Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005, 3:38. BioMed Central Full Text
• [19]Heimberger AB, et al.: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11:1462-1466.
• [20]Zhu X, et al.: Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners. Cancer Immunol Immunother 2010, 59:1401-1409.
• [21]Fujita M, et al.: Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells–Significant Roles of CXCL10. Cancer Res 2009, 69:1587-1595.
• [22]Nishimura F, et al.: Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 2006, 66:4478-4487.
• [23]Ueda R, et al.: Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A 2009, 106:10746-10751.
• [24]Kohanbash G, Okada H: MicroRNAs and STAT interplay. Semin Cancer Biol 2012, 22:70-75.
• [25]Xiao C, et al.: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
• [26]Sasaki K, et al.: miR-17-92 expression in differentiated T cells - Implications for cancer immunotherapy. J Transl Med 2010, 8:17. URL: http://www.translational-medicine.com/content/8/1/17 webcite BioMed Central Full Text
• [27]Stupp R, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
• [28]Salaun B, et al.: Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med 2011, 9:44. BioMed Central Full Text
• [29]Wu T, et al.: Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A 2012, 109:9965-9970.
• [30]Jiang S, et al.: Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 2011, 118:5487-5497.
• [31]Olive V, Li Q, He L: mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 2013, 253:158-166.
• [32]Molitoris JK, McColl KS, Distelhorst CW: Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17 92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 2011, 25:409-420.
• [33]van Haaften G, Agami R: Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 2010, 24:1-4.
• [34]Zhao Y, et al.: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. Cancer Res 2010, 70:9053-9061.
• [35]Morgan RA, et al.: Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053.
• [36]Sampson JH, et al.: Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010, 28:4722-4729.
• [37]Kahlon KS, et al.: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166.
• [38]Kong S, et al.: Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012, 18:5949-5960.
• [39]Ahmed N, et al.: HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. Clin Cancer Res 2010, 16:474-485.
• [40]Chow KK, et al.: T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol Ther 2012, 21:629-637.
• [41]Schulte A, et al.: Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 2012, 18:1901-1913.
• [42]Zhang H, et al.: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007, 179:4910-4918.
• [43]Litterman AJ, et al.: Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol 2013, 190:6259-6268.
• [44]Sanchez-Perez LA, et al.: Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One 2013, 8:e59082.
• [45]Hammond LA, et al.: Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999, 17:2604-2613.
• [46]Sasaki K, et al.: Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007, 67:6451-6458.
• [47]Zhu X, et al.: Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007, 5:10. BioMed Central Full Text
• [48]Okamoto S, et al.: Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer 1996, 73:1366-1372.
• [49]Nakayashiki N, et al.: Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor. Jpn J Cancer Res 2000, 91:1035-1043.